ALNYLAM PHARMACEUTICALS, INC. (ALNY) Operating margin 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) operating margin by fiscal year — reported operating income divided by reported revenue.
13.5%FY2025 · since FY2016: -900.3% → 13.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 13.5% | +21.4 pp |
| FY2024 | -7.9% | +7.6 pp |
| FY2023 | -15.4% | +60.2 pp |
| FY2022 | -75.7% | +8.3 pp |
| FY2021 | -83.9% | +84.2 pp |
| FY2020 | -168.1% | +259.4 pp |
| FY2019 | -427.5% | +660.1 pp |
| FY2018 | -1087.6% | -531.4 pp |
| FY2017 | -556.2% | +344.1 pp |
| FY2016 | -900.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →